MCL1 and nonpapillary renal cell carcinoma: To validate the therapeutic feasibility of MCL1 inhibition in ccRCC, we sought to investigate PRT1419 in a cell-line derived xenograft (CDX) model of PBRM1-mutant ccRCC.